Related Experiment Video
Updated: Sep 18, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
[New s in nephroprotection]
Florence Sens1, Maurice Laville1, Laure Groisne2
1Association pour l'utilisation du rein artificiel en région lyonnaise (AURAL), Lyon, France.
Abstract:
NEWS IN NEPHROPROTECTION. Nephroprotection aims to preserve kidney function and slow the progression of chronic kidney disease. Recent decades have been marked by an expansion of therapeutic options, likely to reduce the number of patients reaching the stage of end-stage renal failure. Among these advances, inhibitors of sodium-glucose cotransport type II (iSGLT2), glucagon like peptide-1 analogues and non-steroidal mineralocorticoid receptor antagonists occupy a central place, in addition to conventional strategies, such as hygienic-dietary measures and blockers of the renin-angiotensin-aldosterone system. This article provides an overview of recent advances in the field of cardio-nephroprotection of adult patients with chronic kidney disease, with particular emphasis on the role and conditions of use of iSGLT2, also called gliflozins.
Insights
Recent advances in nephroprotection, including sodium-glucose cotransport type II inhibitors (iSGLT2), offer new ways to preserve kidney function and slow chronic kidney disease progression in adults.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Nephroprotection strategies aim to preserve kidney function and slow chronic kidney disease (CKD) progression.
- Therapeutic options have expanded significantly, potentially reducing the incidence of end-stage renal failure.
Purpose of the Study:
- To provide an overview of recent advancements in cardio-nephroprotection for adult patients with CKD.
- To emphasize the role and application of sodium-glucose cotransport type II inhibitors (iSGLT2), also known as gliflozins.
Main Methods:
- Review of recent therapeutic advances in nephroprotection.
- Focus on pharmacological interventions including iSGLT2, glucagon-like peptide-1 analogues, and non-steroidal mineralocorticoid receptor antagonists.
- Consideration of conventional strategies like lifestyle modifications and renin-angiotensin-aldosterone system blockers.
Main Results:
- Significant expansion of therapeutic options for CKD management.
- iSGLT2 inhibitors, GLP-1 analogues, and non-steroidal MRAs are key among new treatments.
- Integration of these novel agents with established therapies offers improved cardio-nephroprotective effects.
Conclusions:
- Recent advances, particularly iSGLT2 inhibitors, represent a major step forward in preserving kidney function.
- These therapies are crucial for slowing CKD progression and improving cardiovascular outcomes in affected adults.
- Understanding the specific roles and conditions for using iSGLT2 inhibitors is vital for effective clinical practice.
More Related Videos
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease III: Interprofessional Care

